Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + cytarabine + dexamethasone + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + vincristine
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Intrathecal, Subcutaneous, Intramuscular
01
Overview
A combination chemotherapy regimen containing multiple cytotoxic agents. This intensive multi-drug combination includes alkylating agents (cyclophosphamide, ifosfamide), antimetabolites (cytarabine, methotrexate), an anthracycline (doxorubicin), a topoisomerase inhibitor (etoposide), a vinca alkaloid (vincristine), and a corticosteroid (dexamethasone). Such intensive combinations are typically used for aggressive hematologic malignancies.
02
Targets
TOP2A (DNA topoisomerase II)DNA and topoisomerase II-DNA complexesDHFR (Dihydrofolate reductase)DNA polymerase familyDNAGR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cyclophosphamide + cytarabine + dexamethasone + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + cytarabine + dexamethasone + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + vincristine.